Apogee Therapeutics, Inc. Announces Closing of Upsized Initial Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
18 Juillet 2023 - 10:01PM
Apogee Therapeutics, Inc. (Nasdaq: APGE), a biotechnology company
advancing differentiated biologics for the treatment of atopic
dermatitis, chronic obstructive pulmonary disease, and other
inflammatory and immunology indications (“Apogee” or the
“Company”), today announced the closing of its previously announced
upsized initial public offering of 20,297,500 shares of common
stock, including the full exercise of the underwriters’ option to
purchase up 2,647,500 additional shares, at a public offering price
of $17.00 per share. The aggregate gross proceeds to Apogee from
the offering were approximately $345 million before deducting
underwriting discounts and commissions and other offering expenses
payable by Apogee. All of the shares were offered by Apogee.
The shares began trading on the Nasdaq Global
Market on July 14, 2023 under the ticker symbol “APGE.”
Jefferies, TD Cowen, Stifel and Guggenheim
Securities acted as joint book-running managers for the offering.
Wedbush PacGrow acted as lead manager for the offering.
Registration statements relating to these
securities have been filed with the Securities and Exchange
Commission and became effective on July 13, 2023. The offering was
made only by means of a written prospectus. A copy of the final
prospectus relating to the offering may be obtained from: Jefferies
LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison
Avenue, New York, NY 10022, by telephone at (877) 821-7388, or by
email at Prospectus_Department@Jefferies.com; Cowen and Company,
LLC, 599 Lexington Avenue, New York, NY 10022, by telephone at
(833) 297-2926, or by e-mail at Prospectus_ECM@cowen.com; Stifel,
Nicolaus & Company, Incorporated, Attention: Syndicate, One
Montgomery Street, Suite 3700, San Francisco, CA 94104, by
telephone at (415) 364-2720, or by e-mail at
syndprospectus@stifel.com; or Guggenheim Securities, LLC,
Attention: Equity Syndicate Department, 330 Madison, 8th Floor, New
York, NY 10017, by telephone at (212) 518-9544, or by e-mail at
GSEquityProspectusDelivery@guggenheimpartners.com.
This press release shall not constitute an offer to
sell, or the solicitation of an offer to buy, nor shall there be
any sale of these securities in any state or jurisdiction in which
such offer, solicitation, or sale would be unlawful prior to
registration or qualification under the securities laws of any such
state or jurisdiction.
About Apogee Therapeutics
Apogee Therapeutics, Inc. is a biotechnology
company seeking to develop differentiated biologics for the
treatment of atopic dermatitis (“AD”), chronic obstructive
pulmonary disease (“COPD”) and other inflammatory and immunology
indications with high unmet need. Apogee’s antibody programs are
designed to overcome limitations of existing therapies by targeting
well-established mechanisms of action and incorporating advanced
antibody engineering to optimize half-life and other properties.
The Company’s two most advanced programs are APG777 and APG808,
which are being initially developed for the treatment of AD and
COPD, respectively. Based on a broad pipeline and depth of
expertise, the Company believes it can deliver value and meaningful
benefit to patients underserved by today’s standard of care.
Investor Contact:
Noel KurdiVP of Investor RelationsApogee
Therapeuticsnoel.kurdi@apogeetherapeutics.com
Chelcie ListerTHRUST Strategic
Communicationschelcie@thrustsc.com
Media Contact:
Dan Budwick1AB Mediadan@1abmedia.com
Apogee Therapeutics (NASDAQ:APGE)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024
Apogee Therapeutics (NASDAQ:APGE)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024